Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088442 | 0.78 | ENPP2 (0.41) | — | |
| SCHEMBL564682 | 0.78 | ENPP2 (0.41) | — | |
| SCHEMBL7776146 | 0.78 | CA2 (0.52) | ALDH1A1TDP1KDM4ECA2HTT | |
| Hydrochloric Acid SCHEMBL28847345 | 0.77 | KDM4E (0.57) | ALDH1A1HSD17B10TDP1KDM4ESMN1; SMN2 | |
| SCHEMBL29483829 | 0.76 | SMN1; SMN2 (0.56) | ALDH1A1HSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL17509 | 0.76 | SMN1; SMN2 (0.56) | ALDH1A1HSD17B10TDP1SMN1; SMN2MAPT | |
| SCHEMBL651902 | 0.75 | ALDH1A1 (0.71) | ALDH1A1HSD17B10TDP1HTR6CA2 | |
| SCHEMBL2173113 | 0.75 | GAA (0.44) | ALDH1A1TDP1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL13241046 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL4803286 | 0.74 | SMN1; SMN2 (0.55) | ALDH1A1HSD17B10TDP1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4436667-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118201916-A | Piperazinylsulfonylaryl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| CN-118076594-A | Sulfonylpiperazinyl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| EP-2188272-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV Remynd (BE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010018113-A2 | BI-ARYL AMINOTETRALINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | BLANC JEAN-BAPTISTE | 2010-02-18 | — | — | US | disclosed |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | BLANC JEAN-BAPTISTE | 2010-02-18 | — | — | US | disclosed |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | BLANC JEAN-BAPTISTE | 2010-02-18 | — | — | US | disclosed |
| WO-2010018113-A2 | BI-ARYL AMINOTETRALINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | ABL1, Q6ZSR9, NQO2 | ALDH1A1 2216/4885HSD17B10 3444/4885TDP1 4516/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885HSD17B10 1073/4885TDP1 47/4885 |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | ALDH1A1 3510/4885HSD17B10 2553/4885TDP1 86/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | ALDH1A1 2086/4885HSD17B10 2107/4885TDP1 2352/4885 |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | HRH4, HRH2, HRH1 | ALDH1A1 1036/4885HSD17B10 1713/4885TDP1 4026/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | ALDH1A1 4101/4885HSD17B10 3376/4885TDP1 2245/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885HSD17B10 1073/4885TDP1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.